Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
37,281,723
-
Share change
-
+377,506
-
Total reported value
-
$924,868,486
-
Put/Call ratio
-
12%
-
Price per share
-
$24.79
-
Number of holders
-
95
-
Value change
-
+$10,811,295
-
Number of buys
-
47
-
Number of sells
-
35
Institutional Holders of AIMMUNE THERAPEUTICS INC - COM (AIMT) as of Q3 2017
As of 30 Sep 2017,
AIMMUNE THERAPEUTICS INC - COM (AIMT) was held by
95 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
37,281,723 shares.
The largest 10 holders included
Foresite Capital Management II, LLC, Aisling Capital LLC, FMR LLC, BlackRock Inc., VANGUARD GROUP INC, EAGLE ASSET MANAGEMENT INC, TLP GROUP LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., PRICE T ROWE ASSOCIATES INC /MD/, and Palo Alto Investors, LLC.
This page lists
95
institutional shareholders reporting positions in this security
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.